Recent studies have shown that the ubiquitination and degradation of the cyclin-dependent kinase 2 (CDK2) causes differentiation of AML cells, thus demonstrating the potential of CDK2 inhibitors as differentiation agents in AML [251]. This evidence concerns the gene CDK2 and acute myeloid leukemia.